Australia · Delayed Price · Currency is AUD Bubs Australia Earnings Call Transcripts
Fiscal Year 2026
-
Permanent FDA authorization for three SKUs establishes a strong position in the U.S. premium infant formula market, enabling expansion, innovation, and long-term investment. The company is now present in nearly 12,000 stores nationwide and is pursuing contract manufacturing opportunities.
-
Revenue rose 9.2% to AUD 112 million, led by 24% growth in the U.S., now 59% of total sales. Gross margin was 39.8%, with underlying EBITDA at AUD 5.3 million, despite one-off regulatory and logistics costs. Growth is expected to continue, with FDA approval in the U.S. imminent.
-
A new executive team is driving disciplined global growth in premium infant nutrition, with upgraded FY26 revenue guidance and strong brand positioning in Australia, China, and the U.S. The company is expanding into new markets, investing in supply chain resilience, and shifting marketing to build long-term brand equity with a capital-light, agile model.
-
Revenue rose 14% year-over-year, led by U.S. expansion and strong China performance. Gross margin exceeded 50%, and FY26 revenue is projected to grow 22%-27%. Key risks include currency volatility, tariffs, and regulatory challenges.
Fiscal Year 2025
-
The meeting reviewed strong FY 2025 results, with 23% revenue growth and a focus on U.S. market expansion. Strategic priorities include FDA approval, inventory investment, and a 2030 growth plan. Shareholders voted on key resolutions, and leadership addressed questions on China, tariffs, and future opportunities.
-
Revenue grew 29% to $102.5M, gross margin hit 48%, and positive operating cash flow reached $6.1M, driven by strong U.S. growth and disciplined working capital. Inventory rebuild and margin normalization are expected in FY 2026 as the company invests in marketing and expansion.
-
Delivered first-ever net profit after tax of AUD 3.6 million and 23% revenue growth, driven by strong U.S. and China performance. Gross margin reached 50%, with positive EBITDA and improved cash flow. Confident in FDA approval and permanent U.S. market access in 2025.
Fiscal Year 2024
-
The meeting highlighted strong revenue and margin growth across all regions, successful execution of the first year of a three-year turnaround plan, and a clear path to profitability in FY25. Shareholders' questions focused on margins, cash flow, and governance, with all resolutions put to poll.
-
FY2024 saw 33% revenue growth to AUD 80 million, with strong gains in the US and China, improved gross margins, and reduced cash burn. FY2025 guidance targets 28% revenue growth, positive EBITDA, and continued international expansion.